Paper Details

  1. Home
  2. Paper Details

[Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia].

Author: GorbachevskyS V, ShmaltsA A

Classical ArticleA research paper that has had a significant impact on a specific field. Cited as fundamental research.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review discusses the use of initial combination therapy with PAH-specific drugs in patients with pulmonary arterial hypertension (PAH). Combination therapy may be beneficial in both high-risk and low-risk patients, but further clinical trials are needed.
Paper Details　
Original Abstract of the Article :
Pulmonary arterial hypertension (PAH) is severe and often times rapidly progressive disease with fatal outcome. The concept of initial combination of PAH-specific therapies in high risk patients at baseline was first described in the European guidelines on pulmonary hypertension (PH) in 2009, and in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.26442/00403660.2020.12.000840

データ提供：米国国立医学図書館（NLM）

Combination therapy for pulmonary arterial hypertension: exploring new horizons

Pulmonary arterial hypertension (PAH), a rare but serious condition characterized by high blood pressure in the arteries of the lungs, is a challenging disease to manage. This research delves into the complexities of PAH treatment, focusing on the potential benefits and limitations of using a combination of medications early in the disease course. The authors reviewed studies on initial combination therapy for PAH, considering the specific drugs available in Russia. They found that some combinations, such as ambrisentan plus riociguat, and inhaled iloprost plus sildenafil, showed promising results in terms of improving clinical outcomes. However, they emphasized the need for larger-scale clinical trials to confirm these findings.

Combination therapy for PAH: a promising but complex approach

The review suggests that combination therapy could be a valuable tool for managing PAH. However, it's essential to consider the specific drugs available, the individual patient's risk profile, and the potential for drug interactions.

PAH: navigating a complex desert landscape

If you're living with PAH, it's essential to have open and honest conversations with your healthcare team about the best treatment options for you. Combination therapy might be a valuable approach, but it's important to understand its potential benefits and risks.

Dr.Camel's Conclusion

This review highlights the ever-evolving landscape of PAH treatment. Combination therapy offers a promising approach, but further research is needed to optimize its use and ensure the best possible outcomes for patients.

Date :
  1. Date Completed 2021-03-17
  2. Date Revised 2021-03-17
Further Info :

Pubmed ID

33720578

DOI: Digital Object Identifier

10.26442/00403660.2020.12.000840

Related Literature

Article Analysis
・Effects of macitentan
SNS
PICO Info
in preparation
Languages

Russian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.